July 18, 2017 | Israel’s Therapix Biosciences, a pharmaceutical company dedicated to the development of medicinal marijuana, has signed a memorandum of understanding (MOU) with CURE Pharmaceutical to enter a research collaboration with Assuta Medical Center, Israel’s largest private medical services center. The companies will collaborate to advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids. Therapix Biosciences is a publicly traded company founded in 2004 and is headed by CEO Elran Haber.
Subscribe to NoCamels weekly newsletter and get our top stories
Related posts
Top Tel Aviv Hospital Using AI In Neurological Therapy
April 18, 2024
Israel Foodtech Firms Meet UK Retailers, Investors In London
April 17, 2024
Facebook comments